Nykode Therapeutics AS
Oslo Stock Exchange NYKD.OL
Nykode Therapeutics AS Price to Sales Ratio (P/S) on January 14, 2025: 5.83
-
Nykode Therapeutics AS 52-week high Price to Sales Ratio (P/S) is 42.68 on January 16, 2024, which is 632.39% above the current Price to Sales Ratio (P/S).
-
Nykode Therapeutics AS 52-week low Price to Sales Ratio (P/S) is 4.86 on November 12, 2024, which is -16.56% below the current Price to Sales Ratio (P/S).
-
Nykode Therapeutics AS average Price to Sales Ratio (P/S) for the last 52 weeks is 22.49.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Michael Thyring Engsig |
| IPO Date | Oct. 7, 2020 |
| Location | Norway |
| Headquarters | Oslo Research Park |
| Employees | 179 |
| Sector | Health Care |
| Industries | |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email